

Note : This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

May 7, 2025

To whom it may concern:

TOWA PHARMACEUTICAL CO., LTD.

## Notice of Revisions of Financial Forecasts

In view of its recent financial performance, Towa Pharmaceutical Co., Ltd. (Head office: Kadoma, Osaka; President and Representative Director: Itsuro Yoshida) has revised its consolidated financial forecasts for the fiscal year ending March 31, 2025 (from April 1, 2024 to March 31, 2025), which were previously announced on November 5, 2024, as follows:

### 1. Revision of the consolidated financial forecasts for the fiscal year ending March 31, 2025 (from April 1, 2024 to March 31, 2025)

|                                                                                                      | Net sales       | Operating profit | Ordinary profit | Profit attributable to owners of parent | Earnings per share |
|------------------------------------------------------------------------------------------------------|-----------------|------------------|-----------------|-----------------------------------------|--------------------|
|                                                                                                      | Millions of yen | Millions of yen  | Millions of yen | Millions of yen                         | Yen                |
| Previous forecast (A)                                                                                | 262,100         | 23,300           | 22,700          | 15,000                                  | 304.72             |
| Revised forecast (B)                                                                                 | 259,500         | 23,200           | 26,100          | 18,900                                  | 383.95             |
| Changes (B-A)                                                                                        | -2,600          | -100             | 3,400           | 3,900                                   |                    |
| Percentage changes                                                                                   | -1.0            | -0.4             | 15.0            | 26.0                                    |                    |
| (Reference) Results for the previous fiscal year (Full year of the fiscal year ended March 31, 2024) | 227,934         | 17,647           | 24,477          | 16,173                                  | 328.59             |

### 2. Reason for the revision

With regard to the consolidated financial forecasts for the fiscal year ending March 31, 2025, net sales and operating profit are expected to be roughly in line with the previous forecasts.

Ordinary profit and profit attributable to owners of parent are expected to exceed the previous forecasts, mainly due to 1.9 billion yen in foreign exchange gains, a 1.2 billion yen gain on valuation of derivatives, and effectively utilizing tax incentives, which resulted in the tax rate being approximately 6% lower than anticipated.

The previous forecasts were based on the assumption that 1.4 billion yen in foreign exchange gains and a loss of 1.2 billion yen on valuation of derivatives recorded in the first half would be recorded as is for the full year.

Note: The above forecasts were prepared on the basis of available information at the time of the release of this notice. Actual performance may differ from the forecasts due to various factors in the future.

End of Notice